ZyVersa Competitors
| ZVSA Stock | 0.17 0.01 6.25% |
ZyVersa Therapeutics vs Biomotion Sciences Correlation
Very good diversification
The correlation between ZyVersa Therapeutics and SLXN is -0.33 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and SLXN in the same portfolio, assuming nothing else is changed.
Moving against ZyVersa Stock
| 0.47 | LYRA | Lyra Therapeutics | PairCorr |
| 0.47 | BCT | Briacell Therapeutics | PairCorr |
| 0.31 | IMNN | Imunon Inc | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ZyVersa Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ZyVersa Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ZyVersa Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ZyVersa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ZyVersa Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ZyVersa Stock performing well and ZyVersa Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ZyVersa Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HEPA | 8.69 | (5.49) | 0.00 | 1.71 | 0.00 | 13.95 | 78.13 | |||
| CDT | 4.62 | (1.47) | 0.00 | (0.44) | 0.00 | 10.06 | 32.20 | |||
| ENVB | 7.28 | (0.63) | 0.00 | (0.26) | 0.00 | 14.08 | 121.83 | |||
| XAGE | 6.86 | (0.74) | 0.00 | (0.19) | 0.00 | 18.75 | 46.80 | |||
| NIVF | 7.40 | (3.33) | 0.00 | (1.77) | 0.00 | 15.95 | 44.03 | |||
| WORX | 5.50 | (0.14) | 0.00 | 0.39 | 0.00 | 10.34 | 57.56 | |||
| INDP | 5.85 | (0.52) | 0.00 | (0.13) | 0.00 | 13.58 | 51.64 | |||
| JSPR | 4.22 | (0.46) | 0.00 | 0.53 | 0.00 | 7.73 | 31.75 | |||
| ONCO | 4.88 | (1.17) | 0.00 | 7.14 | 0.00 | 9.09 | 36.81 | |||
| SLXN | 4.15 | (0.86) | 0.00 | (0.37) | 0.00 | 15.09 | 37.24 |
Cross Equities Net Income Analysis
Compare ZyVersa Therapeutics and related stocks such as Hepion Pharmaceuticals, Conduit Pharmaceuticals, and Enveric Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDT | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (4.9 M) | (535 K) | (17.8 M) | (16 M) | (15.2 M) |
| ENVB | (1.2 M) | (33.4 K) | (24.6 K) | (161) | (33.6 K) | (1.9 M) | (2.8 M) | (9.1 M) | (16.9 M) | (5.6 M) | (6.9 M) | (49 M) | (18.5 M) | (17.3 K) | (9.6 M) | (8.6 M) | (8.2 M) |
| XAGE | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (9.1 M) | (15.4 M) | (10.4 M) | (9.3 M) | (9.8 M) |
| NIVF | (533) | (533) | (533) | (533) | (533) | (533) | (533) | (533) | (533) | (533) | (533) | (533) | 458.7 K | (690.9 K) | (525 K) | (472.5 K) | (448.9 K) |
| WORX | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (386.5 K) | (4.2 M) | (12 M) | (14.6 M) | (11.5 M) | (7.4 M) | (3.8 M) | (1.8 M) | (4 M) | (1.1 M) | (1.3 M) | (1.4 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| ONCO | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (1.6 M) | (3.4 M) | (13.4 M) | (37.4 M) | (58.7 M) | (52.8 M) | (50.2 M) |
| SLXN | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (755.2 K) | (3.2 M) | (4.9 M) | (16.4 M) | (14.8 M) | (14.1 M) |
ZyVersa Therapeutics and related stocks such as Hepion Pharmaceuticals, Conduit Pharmaceuticals, and Enveric Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ZyVersa Therapeutics financial statement analysis. It represents the amount of money remaining after all of ZyVersa Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.ZyVersa Therapeutics Competitive Analysis
The better you understand ZyVersa Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ZyVersa Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ZyVersa Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
ZyVersa Therapeutics Competition Performance Charts
Five steps to successful analysis of ZyVersa Therapeutics Competition
ZyVersa Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ZyVersa Therapeutics in relation to its competition. ZyVersa Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of ZyVersa Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ZyVersa Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ZyVersa Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your ZyVersa Therapeutics position
In addition to having ZyVersa Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recycling Thematic Idea Now
Recycling
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ZyVersa Therapeutics Correlation with its peers. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. Anticipated expansion of ZyVersa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ZyVersa Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate ZyVersa Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating ZyVersa Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause ZyVersa Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, ZyVersa Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.